Rocket Lab clears antitrust and raises $1.94bn for Iridium
What happened
Rocket Lab filed an 8-K (Item 7.01/8.01/9.01, accession 0001753926-26-001463) disclosing a "dollar-for-dollar replacement" At-The-Market equity distribution agreement with Deutsche Bank Securities and Wells Fargo Securities for up to $1,944,369,826 in common stock/forward sales — the company's own same-day release states it intends to use the proceeds to fund cash payments under the pending Iridium acquisition, reducing the $3.6bn bridge-loan draw. A companion same-day release ("Announces Progress on Iridium Acquisition") confirms: the HSR antitrust waiting period lapsed 11:59pm ET Aug 12 2026; Rocket Lab filed Form S-4 to register the merger securities (not yet effective, stockholder vote still pending); and Rocket Lab/Iridium filed Aug 10 to transfer control of Iridium's FCC licenses. A second, related 8-K (accession 0001753926-26-001454) files Iridium's audited FY2024/FY2025 financials and Rocket Lab's pro forma combined statements into the registration statements per the Merger Agreement.
Read-across for SES
The Iridium deal's antitrust/regulatory path is now clear (HSR done, FCC transfer filed) and its financing mechanics are live — this is the acquisition that hands Rocket Lab Iridium's USSF EMSS/GMDSS/DoD PTT government contracts, the exact book SES/Intelsat General competes on. Funding via a $1.94bn equity raise rather than pure debt is a capital-structure signal worth tracking against RKLB's stock reaction over the next few sessions.
As the brief filed it
[AGE: 16h] Rocket Lab clears HSR antitrust review for its Iridium buyout, files Form S-4 and FCC license-transfer applications, and launches a $1.94bn ATM stock program explicitly to fund the deal's cash payments.